GlassScriptPhysician profile
Mylan N Lam
NPI 1114915469
$1,230.62
in general payments reported to CMS, 2019-2025
24 companies · $368 in 2025
The $368 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172 · 2020: $36.77 · 2021: $14.92 · 2023: $289 · 2024: $350 · 2025: $368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,006.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,006.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $194.57 | 2023-2025 | |
| Baxter Healthcare | $143.59 | 2024 | Actifuse |
| Coloplast Corp | $128.12 | 2019-2025 | Speedicath |
| C. R. Bard, INC. & Subsidiaries | $111.13 | 2025 | Bard Urinary Drainage Bag |
| Merz Pharmaceuticals, LLC | $110.24 | 2023-2025 | Xeomin, Inbrija |
| Medtronic, INC. | $99.16 | 2023 | Synchromedii |
| Argenx US, INC. | $69.88 | 2024-2025 | Vyvgart Hytrulo |
| Azurity Pharmaceuticals, INC. | $67.22 | 2023-2025 | Horizant, Horizant |
| Allergan, INC. | $45.75 | 2019-2021 | |
| Merz North America, INC. | $34.95 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $29.50 | 2024-2025 | |
| Abbott Laboratories | $20.36 | 2019 | |
| Amgen INC. | $20.03 | 2025 | Repatha |
| Axsome Therapeutics, INC. | $17.95 | 2023 | Sunosi |
| Otsuka America Pharmaceutical, INC. | $16.27 | 2023 | Nuedexta |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $15.52 | 2024 | Vyepti |
| Pfizer INC. | $14.93 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $14.14 | 2019 | |
| Biogen, INC. | $14.05 | 2019 | |
| Tersera Therapeutics LLC | $14.04 | 2019 | |
| Alexion Pharmaceuticals, INC. | $13.44 | 2020 | |
| Biodelivery Sciences International, INC. | $12.45 | 2019 | |
| Avanir Pharmaceuticals, INC. | $11.93 | 2020 | |
| Vertical Pharmaceuticals, LLC | $11.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mylan Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.